vs

Side-by-side financial comparison of CVRx, Inc. (CVRX) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.

CVRx, Inc. is the larger business by last-quarter revenue ($16.0M vs $13.2M, roughly 1.2× TriSalus Life Sciences, Inc.). TriSalus Life Sciences, Inc. runs the higher net margin — -73.9% vs -74.5%, a 0.6% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs 4.4%). TriSalus Life Sciences, Inc. produced more free cash flow last quarter ($-2.5M vs $-9.8M). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs 22.0%).

CVRx, Inc. is a commercial-stage medical technology company specializing in neuromodulation therapies for chronic cardiovascular diseases. Its flagship Barostim system treats heart failure and resistant hypertension, with core markets across North America and Europe, serving patients unresponsive to conventional drug treatments.

TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.

CVRX vs TLSI — Head-to-Head

Bigger by revenue
CVRX
CVRX
1.2× larger
CVRX
$16.0M
$13.2M
TLSI
Growing faster (revenue YoY)
TLSI
TLSI
+55.4% gap
TLSI
59.8%
4.4%
CVRX
Higher net margin
TLSI
TLSI
0.6% more per $
TLSI
-73.9%
-74.5%
CVRX
More free cash flow
TLSI
TLSI
$7.3M more FCF
TLSI
$-2.5M
$-9.8M
CVRX
Faster 2-yr revenue CAGR
TLSI
TLSI
Annualised
TLSI
43.0%
22.0%
CVRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CVRX
CVRX
TLSI
TLSI
Revenue
$16.0M
$13.2M
Net Profit
$-11.9M
$-9.8M
Gross Margin
86.3%
86.7%
Operating Margin
-69.8%
-24.8%
Net Margin
-74.5%
-73.9%
Revenue YoY
4.4%
59.8%
Net Profit YoY
-12.0%
3.5%
EPS (diluted)
$-0.45
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVRX
CVRX
TLSI
TLSI
Q4 25
$16.0M
$13.2M
Q3 25
$14.7M
$11.6M
Q2 25
$13.6M
$11.2M
Q1 25
$12.3M
$9.2M
Q4 24
$15.3M
$8.3M
Q3 24
$13.4M
$7.3M
Q2 24
$11.8M
$7.4M
Q1 24
$10.8M
$6.5M
Net Profit
CVRX
CVRX
TLSI
TLSI
Q4 25
$-11.9M
$-9.8M
Q3 25
$-12.9M
$-10.8M
Q2 25
$-14.7M
$-8.3M
Q1 25
$-13.8M
$-10.4M
Q4 24
$-10.7M
$-10.1M
Q3 24
$-13.1M
$-2.4M
Q2 24
$-14.0M
$-4.3M
Q1 24
$-22.2M
$-13.2M
Gross Margin
CVRX
CVRX
TLSI
TLSI
Q4 25
86.3%
86.7%
Q3 25
86.8%
83.5%
Q2 25
84.3%
83.9%
Q1 25
83.5%
83.7%
Q4 24
83.2%
85.3%
Q3 24
83.2%
86.3%
Q2 24
83.9%
87.6%
Q1 24
85.0%
85.0%
Operating Margin
CVRX
CVRX
TLSI
TLSI
Q4 25
-69.8%
-24.8%
Q3 25
-83.5%
-77.9%
Q2 25
-105.8%
-65.4%
Q1 25
-108.8%
-79.9%
Q4 24
-67.0%
-91.8%
Q3 24
-97.3%
-118.9%
Q2 24
-118.3%
-111.0%
Q1 24
-206.4%
-180.8%
Net Margin
CVRX
CVRX
TLSI
TLSI
Q4 25
-74.5%
-73.9%
Q3 25
-87.6%
-93.5%
Q2 25
-108.4%
-73.9%
Q1 25
-111.5%
-113.2%
Q4 24
-69.4%
-122.4%
Q3 24
-98.0%
-32.6%
Q2 24
-118.8%
-58.8%
Q1 24
-206.0%
-204.5%
EPS (diluted)
CVRX
CVRX
TLSI
TLSI
Q4 25
$-0.45
$-0.22
Q3 25
$-0.49
$-0.96
Q2 25
$-0.57
$-0.27
Q1 25
$-0.53
$-0.39
Q4 24
$-0.39
$-0.38
Q3 24
$-0.57
$-0.12
Q2 24
$-0.65
$-0.21
Q1 24
$-1.04
$-0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVRX
CVRX
TLSI
TLSI
Cash + ST InvestmentsLiquidity on hand
$75.7M
$20.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$39.3M
$-33.9M
Total Assets
$104.8M
$35.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVRX
CVRX
TLSI
TLSI
Q4 25
$75.7M
$20.4M
Q3 25
$85.1M
$22.7M
Q2 25
$95.0M
$26.5M
Q1 25
$102.7M
$13.0M
Q4 24
$105.9M
$8.5M
Q3 24
$100.2M
$11.3M
Q2 24
$70.4M
$16.5M
Q1 24
$80.1M
$4.0M
Stockholders' Equity
CVRX
CVRX
TLSI
TLSI
Q4 25
$39.3M
$-33.9M
Q3 25
$48.1M
$-26.7M
Q2 25
$57.9M
$-19.4M
Q1 25
$71.1M
$-34.4M
Q4 24
$71.1M
$-25.9M
Q3 24
$65.2M
$-20.4M
Q2 24
$55.2M
$-25.3M
Q1 24
$66.3M
$-36.0M
Total Assets
CVRX
CVRX
TLSI
TLSI
Q4 25
$104.8M
$35.3M
Q3 25
$111.3M
$36.5M
Q2 25
$119.6M
$41.3M
Q1 25
$129.6M
$28.6M
Q4 24
$133.4M
$24.0M
Q3 24
$127.7M
$27.5M
Q2 24
$96.0M
$32.4M
Q1 24
$106.2M
$17.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVRX
CVRX
TLSI
TLSI
Operating Cash FlowLast quarter
$-9.8M
$-2.5M
Free Cash FlowOCF − Capex
$-9.8M
$-2.5M
FCF MarginFCF / Revenue
-61.3%
-19.1%
Capex IntensityCapex / Revenue
0.4%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-40.8M
$-19.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVRX
CVRX
TLSI
TLSI
Q4 25
$-9.8M
$-2.5M
Q3 25
$-9.7M
$-3.7M
Q2 25
$-7.9M
$-7.3M
Q1 25
$-12.8M
$-4.5M
Q4 24
$-8.0M
$-5.7M
Q3 24
$-10.4M
$-10.8M
Q2 24
$-9.8M
$-13.4M
Q1 24
$-10.9M
$-10.9M
Free Cash Flow
CVRX
CVRX
TLSI
TLSI
Q4 25
$-9.8M
$-2.5M
Q3 25
$-10.0M
$-3.9M
Q2 25
$-8.0M
$-7.4M
Q1 25
$-12.9M
$-5.3M
Q4 24
$-8.1M
$-5.8M
Q3 24
$-10.4M
$-11.0M
Q2 24
$-10.2M
$-13.5M
Q1 24
$-11.8M
$-10.9M
FCF Margin
CVRX
CVRX
TLSI
TLSI
Q4 25
-61.3%
-19.1%
Q3 25
-68.1%
-33.9%
Q2 25
-59.2%
-66.1%
Q1 25
-104.3%
-57.3%
Q4 24
-52.5%
-69.7%
Q3 24
-78.1%
-149.9%
Q2 24
-86.3%
-183.1%
Q1 24
-109.7%
-169.3%
Capex Intensity
CVRX
CVRX
TLSI
TLSI
Q4 25
0.4%
0.3%
Q3 25
2.0%
1.9%
Q2 25
0.8%
0.8%
Q1 25
0.9%
8.2%
Q4 24
0.3%
0.6%
Q3 24
0.3%
2.3%
Q2 24
3.0%
0.8%
Q1 24
8.5%
1.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CVRX
CVRX

US$14.9M93%
Other$1.1M7%

TLSI
TLSI

Segment breakdown not available.

Related Comparisons